Objective To study the efficacy of fluoxetine for the patients with persist somatoform pain disorder and the relationship
between the efficacy of fluoxetine and serotonin 2A (5 HT 2A ) receptor gene T102C
polymorphism Methods Sixty two patients who met with ICD 10 criteria for persist somatoform pain disorder (F45 4) were treated with fluoxetine (20 mg/day) for 6 weeks The Medical Outcome Study Pain Measures (MOSPM) and Hamilton Depression Scale (HAMD) 17 items were used to assess the therapeutic efficacy According to the efficacy rate of MOSPM, the patients were divided into responder or non responder group Fifty one patients were examined the genotypes and allele frequencies of 5 HT 2A receptor gene T102C polymorphism with polymerase chain reaction
restriction fragment length polymorphism (PCR RFLP) Results The efficacy rate of fluoxetine on the score of MOSPM were 19%, 48% and 76% at the 2 nd, 4 th and 6 th weekend respectively, and the effect rate of antidepressant were 24%, 56% and 79% according to HAMD score There were significant difference of T/T, C/C genotypes and T,C alleles between the responder group and non responder group( Z =3 165, 3 822, 3 125, 3 125, respectively), but no difference were found in T/C genotype( Z =0 463) Conclusion Fluoxetine can alleviate the pain and depressive symptoms of the patients with persist somatoform pain disorder, and there may be some relation between the analgesic efficacy of fluoxetine and 5 HT 2A receptor gene T102C polymorphism